Title : BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Pub. Date : 2013 Jan 17

PMID : 23223358






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens